

# The ENHANCE Study: taVNS and Psilocybin

NCT05866471

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	University of Wisconsin, Madison
<b>Enrollment</b>	108 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- English speaking
- Ability/willingness to complete all study activities
- Modest reduction in emotional well-being
- Medically healthy (does not meet criteria for an exclusionary medical condition)
- Blood pressure and heart rate within established ranges at screening
- ... and 1 more (see full listing online)

### Exclusion (12)

- Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)
- Current or clinically significant psychiatric disorder that, in the investigator's judgment, would interfere with participation or increase risk
- Current use of drugs or medications, prescribed or otherwise, that may interact with psilocybin
- Use of investigational drugs, biologics, or devices within 30 days of enrollment
- Use of psychedelic or related agents within three months of Dosing Day
- ... and 7 more (see full listing online)

## Locations (1 total)

---

University of Wisconsin - Madison, Madison, Wisconsin, United States